First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status

Hwang,Jun-Eul; Kim,Ha-Na; Kim,Dae-Eun; Shim,Hyun-Jeong; Bae,Woo-Kyun; Hwang,Eu-Chang; Cho,Sang-Hee; Chung,Ik-Joo

doi:10.3892/etm.2012.644

First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status

Authors:
- Jun-Eul Hwang
- Ha-Na Kim
- Dae-Eun Kim
- Hyun-Jeong Shim
- Woo-Kyun Bae
- Eu-Chang Hwang
- Sang-Hee Cho
- Ik-Joo Chung
View Affiliations

Affiliations: Division of Hematology-Οncology, Department of Internal Μedicine, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea, Department of Urology, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea
Published online on: July 23, 2012 https://doi.org/10.3892/etm.2012.644
Pages: 562-568

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Combination chemotherapy is a standard treatment approach in advanced gastric cancer. However, combination chemotherapy for advanced gastric cancer is often associated with severe treatment-related toxicities and most oncologists are reluctant to perform combination chemotherapy in patients with a poor clinical condition. We retrospectively investigated the efficacy and tolerability of single-agent chemotherapy in patients with recurrent or metastatic gastric cancer with poor performance status (PS). We reviewed advanced gastric adenocarcinoma patients who received first-line single-agent palliative chemotherapy due to poor PS between June 2006 and December 2010. A total of 125 patients with Eastern Cooperative Oncology Group (ECOG) PS 2-3, whose general condition did not allow combination chemotherapy, were enrolled. Four single agents were used: TS-1 (n=63), paclitaxel (n=42), irinotecan (n=15) and capecitabine (n=5). The median age was 66 years, with a range of 25-81 years. The percent response rate and rate of stable disease (SD) were 19.2 and 35.2%, respectively, giving a disease control rate of 54.4%. The median progression-free survival (PFS) was 3.9 months (95% CI, 2.73-5.06). The median overall survival (OS) was 9.1 months (95% CI, 7.70-10.56) with a 1-year survival rate of 31.2%. Multivariate analysis demonstrated that the independent prognostic factors for OS were chemotherapy regimen (capecitabine) [reference: TS-1, hazard ratio (HR), 5.00; 95% CI, 1.81-13.81; P=0.002], no second-line chemotherapy (HR, 2.3; 95% CI, 1.48-3.57; P=0.001), bone metastasis (HR, 2.73; 95% CI, 1.22-6.09; P=0.014), ECOG PS 3 (HR, 38.10; 95% CI, 13.72-105.78; P=0.001), Glasgow prognostic score (GPS) ≥1 (HR, 1.88; 95% CI, 1.24-2.85; P=0.003) and chemotherapy response [SD + progressive disease (PD) + not evaluable (NE); HR, 2.37; 95% CI, 1.39-4.05; P=0.002)]. First-line single-agent palliative chemotherapy demonstrated a relatively good clinical efficacy for recurrent or metastatic gastric cancer patients with poor PS.

View Figures

View References

1	Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
2	Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
3	Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 18:2648–2657. 2000.
4	Lavin PT, Bruckner HW and Plaxe SC: Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer. 50:2016–2023. 1982. View Article : Google Scholar : PubMed/NCBI
5	Wilson D, Hiller L and Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol). 17:81–90. 2005. View Article : Google Scholar : PubMed/NCBI
6	Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
7	Lee J, Lim T, Uhm JE, et al: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 18:886–891. 2007. View Article : Google Scholar : PubMed/NCBI
8	Chau I, Norman AR, Cunningham D, Waters JS, Oates J and Ross PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 22:2395–2403. 2004. View Article : Google Scholar
9	Cunningham D, Hole D, Taggart DJ, Soukop M, Carter DC and McArdle CS: Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival. Br J Surg. 74:715–720. 1987. View Article : Google Scholar : PubMed/NCBI
10	Hsu CH, Yeh KH, Chen LT, et al: Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology. 54:275–280. 1997. View Article : Google Scholar : PubMed/NCBI
11	Lim do H, Park SH, Park KW, et al: Retrospective analyses of cisplatin-based doublet combination chemotherapy in patients with advanced gastric cancer. BMC Cancer. 10:5832010.PubMed/NCBI
12	Jeung HC, Rha SY, Shin SJ, Ahn JB, Noh SH, Roh JK and Chung HC: A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer. 97:4584–4563. 2007. View Article : Google Scholar : PubMed/NCBI
13	Hosokawa A, Sugiyama T, Ohtsu A, et al: Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol. 42:533–538. 2007. View Article : Google Scholar : PubMed/NCBI
14	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
15	Egawa T, Kubota T, Nagashima A, et al: Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer. Gan To Kagaku Ryoho. 31:877–881. 2004.(In Japanese).
16	Futatsuki K, Wakui A, Nakao I, et al: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho. 21:1033–1038. 1994.(In Japanese).
17	Kang JH, Lee SI, Lim DH, et al: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 30:1513–1518. 2012. View Article : Google Scholar : PubMed/NCBI
18	Bang YJ: Capecitabine in gastric cancer. Expert Rev Anticancer Ther. 11:1791–1806. 2011. View Article : Google Scholar : PubMed/NCBI
19	Hwang JE, Kim HN, Kim DE, et al: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 11:4892011. View Article : Google Scholar
20	Maehara Y, Sugimachi K, Ogawa M, Kakegawa T, Shimazu H and Tomita M: Influence of preoperative performance status on survival time of patients with advanced gastric cancer following noncurative resection. Anticancer Res. 13:201–203. 1993.PubMed/NCBI
21	Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
22	Koizumi W, Akiya T, Sato A, et al: Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. Cancer Chemother Pharmacol. 65:1093–1099. 2010.PubMed/NCBI
23	Tsushima T, Hironaka S, Boku N, et al: Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer. Gastric Cancer. 13:245–250. 2010. View Article : Google Scholar : PubMed/NCBI
24	Pasini F, Fraccon AP and DE Manzoni G: The role of chemo-therapy in metastatic gastric cancer. Anticancer Res. 31:3543–3554. 2011.
25	Ando T, Hosokawa A, Kajiura S, et al: Efficacy of weekly paclitaxel in patients with advanced gastric cancer: refractory to docetaxel-based chemotherapy. Gastric Cancer. Jan 18–2012.(Epub ahead of print).